# Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection

> **NCT03147859** · PHASE2 · UNKNOWN · sponsor: **Ottawa Hospital Research Institute** · enrollment: 10 (estimated)

## Conditions studied

- HIV-infection/AIDS

## Interventions

- **BIOLOGICAL:** Vedolizumab (brand name Entyvio)

## Key facts

- **NCT ID:** NCT03147859
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2023-05-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03147859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03147859, "Vedolizumab Treatment in Antiretroviral Drug Treated Chronic HIV Infection". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03147859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*